Related Experiment Video
Updated: Jun 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Role of neutralizing anti-interferon antibodies during interferon therapy in patients with chronic hepatitis B]
1The Fifth People's Hospital of Suzhou 215007, China.
Objective:
Investigation in the role of neutralizing anti-interferon antibodies(NA) during interferon therapy in patients with chronic hepatitis B.
Methods:
To measure the levels of NA in 48 patients with chronic hepatitis B (CHB) treated with interferon-alpha (IFN-alpha) at the point before treated and at 3 and 6 months with treatment respectively. At the same time to measure the levels of NA in health volunteers.
Results:
NA can not be measured in health volunteers and those patients with CHB at the point before treated. At the point of 6 months with treatment, 15 patients with CHB got complete respond, 10 patients with CHB got no respond, 23 patients with CHB got partly respond, respectively. NA positive rate was 25% at 3 months and 37.5% at 6 months with treatment, respectively. (P > 0.05). NA positive rate was significantly higher in complete responders group and partly responders group than in no responders group at 3 months with. NA positive rate was significantly higher in complete responders group than in no responders group at 3 months with.
Conclusion:
NA can be measured in blood serum after treated with interferon. NA influences the efficacy of interferon, especially at 3 months.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Inhibitors Of Virion Release
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
